Novartis: Asthma trials

The registry lists 105 Asthma studies with Novartis as lead sponsor. 3 are open to participants now and 61 have results posted.

Phase 1 8Phase 2 49Phase 3 33Phase 4 13No phase 8(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.RecruitingNCT05776927Phase 3
• A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With AsthmaRecruitingNCT05562466Phase 3
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With AsthmaRecruitingNCT05222529Phase 2
• Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With AsthmaCompletedNCT04589663Phase 2Results posted
• Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled AsthmaTerminatedNCT04410523Phase 2Results posted
• Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma PatientsTerminatedNCT03944707Phase 2Results posted
• Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and AsthmaCompletedNCT03681093Phase 3Results posted
• Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With AsthmaTerminatedNCT03650400Phase 2Results posted
• Systemic Corticosteroids Avoidance Study in Severe Asthma PatientsTerminatedNCT03629249Phase 3Results posted
• Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe AsthmaCompletedNCT03299686Phase 2Results posted
• Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.CompletedNCT03257995Phase 2Results posted
• Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled AsthmaCompletedNCT03226392Phase 3Results posted
• Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled AsthmaCompletedNCT03215758Phase 3Results posted
• Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + TiotropiumCompletedNCT03158311Phase 3Results posted
• Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in AsthmaCompletedNCT03137784Phase 2/3Results posted
• Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With AsthmaCompletedNCT03108027Phase 2Results posted
• A Long-term Safety Study of QVM149 in Japanese Patients With AsthmaCompletedNCT03100825Phase 3Results posted
• A Long-term Safety Study of QMF149 in Japanese Participants With AsthmaCompletedNCT03100500Phase 3Results posted
• Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.CompletedNCT03063086Phase 2Results posted
• Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma TreatmentTerminatedNCT03052517Phase 3Results posted
• Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With AsthmaCompletedNCT02892344Phase 3Results posted
• Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With AsthmaCompletedNCT02892019Phase 2Results posted
• Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaCompletedNCT02571777Phase 3Results posted
• Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.CompletedNCT02563067Phase 3Results posted
• Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.CompletedNCT02555683Phase 3Results posted
• A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With AsthmaCompletedNCT02554786Phase 3Results posted
• Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With AsthmaTerminatedNCT02336425Phase 2Results posted
• Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201TerminatedNCT02075008Phase 2Results posted
• Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent AsthmaCompletedNCT01959412Phase 2Results posted
• Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated AsthmaTerminatedNCT01912872Phase 4Results posted
• Study of Safety of Foradil in Patients With Persistent AsthmaTerminatedNCT01845025Phase 4Results posted
• A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic PatientsCompletedNCT01836471Phase 2Results posted
• Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With AsthmaCompletedNCT01716754Phase 2Results posted
• Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent AsthmaCompletedNCT01609478Phase 2Results posted
• Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent AsthmaCompletedNCT01555151Phase 2Results posted
• A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 DeviceCompletedNCT01484197Phase 2Results posted
• A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe AsthmaCompletedNCT01479595Phase 2Results posted
• Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled AsthmaTerminatedNCT01478360Phase 2Results posted
• Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 TherapyCompletedNCT01202903Phase 3Results posted
• Efficacy, Safety and Pharmacokinetics of Different Regimens of IndacaterolCompletedNCT01156844Phase 2Results posted
• Efficacy and Safety of Different Doses of IndacaterolCompletedNCT01079130Phase 3Results posted
• Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon DevicesCompletedNCT01012739Phase 2Results posted
• Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled AsthmaCompletedNCT01007149Phase 3Results posted
• Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With AsthmaCompletedNCT00941798Phase 2Results posted
• Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With AsthmaCompletedNCT00927901Phase 2Results posted
• Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product AdvairCompletedNCT00927758Phase 2Results posted
• Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic AsthmaCompletedNCT00870584Phase 4Results posted
• Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent AsthmaCompletedNCT00746330Phase 2Results posted
• Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonistsCompletedNCT00670930Phase 4Results posted
• A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE LevelsCompletedNCT00624832Phase 4Results posted
• Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate AsthmaCompletedNCT00605306Phase 2Results posted
• Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic AsthmaCompletedNCT00567476Phase 4Results posted
• Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent AsthmaCompletedNCT00557440Phase 2Results posted
• Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With AsthmaCompletedNCT00556673Phase 2Results posted
• A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent AsthmaCompletedNCT00545272Phase 2Results posted
• Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent AsthmaCompletedNCT00529529Phase 3Results posted
• Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.CompletedNCT00500539Phase 3Results posted
• Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial ObstructionCompletedNCT00460577Phase 4Results posted
• Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic AsthmaCompletedNCT00454051Phase 4Results posted
• Dose Ranging Study for Indacaterol in Japanese Asthma PatientsCompletedNCT00403754Phase 2Results posted
• Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic RhinoconjunctivitisCompletedNCT00396409Phase 3Results posted
• Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic AsthmaCompletedNCT00264849Phase 4Results posted
• Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease ModificationTerminatedNCT00124709Phase 4Results posted
• Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic AsthmaCompletedNCT00079937Phase 3Results posted
• Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.CompletedNCT05424523
• A 24-week rPMS Study in Real-world Setting for EnerzairActive, not recruitingNCT05274425
• A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®Active, not recruitingNCT05217810
• XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United StatesCompletedNCT05157087
• An Observational Prospective Study to Characterize Patients Initiating Enerzair® Breezhaler®, With or Without Sensor, as a Maintenance Treatment for AsthmaWithdrawnNCT05120986
• Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled AsthmaTerminatedNCT04946318Phase 2
• Digital Adherence Monitoring of Inhalative Therapy in Real- Life ConditionsCompletedNCT04656223
• Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.WithdrawnNCT03989635Phase 2
• A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic AsthmaCompletedNCT03138811Phase 1
• Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic SubjectsCompletedNCT02758548Phase 2
• Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled AsthmaWithdrawnNCT02127697Phase 3
• A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test FixtureWithdrawnNCT01845623Phase 2
• A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic AsthmaCompletedNCT01703312Phase 1/2
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male SubjectsCompletedNCT01596712Phase 1
• To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With AsthmaCompletedNCT01568762Phase 1
• Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent AsthmaCompletedNCT01545726Phase 2
• Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and HospitalizationsWithdrawnNCT01460862
• Dose Finding Study for QAW039 in AsthmaCompletedNCT01437735Phase 2
• Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic AsthmaCompletedNCT01362621
• Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese ChildrenCompletedNCT01328886Phase 3
• Efficacy, Safety, and Pharmacokinetics of QAW039CompletedNCT01253603Phase 2
• Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)CompletedNCT01155700Phase 3
• Efficacy of QAX576 in AsthmaCompletedNCT01130064Phase 2
• Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With AsthmaTerminatedNCT01103037Phase 2
• Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in AsthmaticsWithdrawnNCT00997477Phase 4
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma PatientsCompletedNCT00940160Phase 1/2
• Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma PatientsCompletedNCT00814216Phase 2
• A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate AsthmaCompletedNCT00785083Phase 2
• A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal TherapyCompletedNCT00639691Phase 4
• Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent AsthmaCompletedNCT00624702Phase 1
• Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic AsthmaWithdrawnNCT00598104Phase 1/2
• Safety and Tolerability of Omalizumab in Patients With Mild to Moderate AsthmaCompletedNCT00546143Phase 4
• Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma PatientsCompletedNCT00482508Phase 3
• Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic AsthmaCompletedNCT00482248Phase 3
• Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)CompletedNCT00443482Phase 2
• A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial AsthmaCompletedNCT00411567Phase 1/2